

Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations.
Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Owner
Owner
Owner
Owner
Owner
Owner
Contributor
Therapeutic Relevance
The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project targets well-characterized aging pathways (DNA damage, epigenetic drift, inflammatory signaling, mitochondrial dysfunction) using single-cell transcriptomic data from ~850,000 transcriptomes spanning ages 23–91, providing a robust foundation. The identified targets (NR4A1/2, CD38, UHRF1, CCR9, etc.) are biologically relevant and supported by existing literature. However, the score is not a 5 because: (1) all evidence is computational/bioinformatic with zero experimental validation to date, (2) the multi-modal intervention strategy (simultaneously modulating many targets) adds complexity and uncertainty about which targets are truly causal vs. correlative, and (3) the AubrAI-generated hypothesis, while interesting, is AI-generated and unvalidated. The scientific rationale is strong but remains entirely theoretical at this stage.
Therapeutic Optionality
The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline, anemia, susceptibility to infections, myelodysplastic syndromes, leukemia prevention, and broader healthy aging/regenerative medicine applications. The multi-modal approach (mRNA, siRNA, small molecules, CRISPR, gene therapy, nanoparticle delivery) provides flexibility in intervention modality. The identified targets span inflammation, epigenetics, metabolism, and differentiation — each potentially applicable to different disease contexts beyond HSC aging. The platform approach (scRNA-seq + AI/ML GRN analysis) could theoretically be applied to other stem cell types. A score of 5 is not warranted because the concept is still narrowly focused on HSCs specifically, and the breadth of application remains speculative without any validated proof points.
Intellectual Property
The IP position is moderate with both strengths and risks. Strengths: the specific combination of targets identified through their proprietary computational pipeline and the multi-modal temporal intervention strategy could be novel and patentable; the use of proprietary datasets alongside public data adds some differentiation; no patents have been filed yet but patent filing is a stated project outcome. Risks: (1) many of the individual targets (CD38, NR4A1/2, RhoA, mTOR/rapamycin) are well-known in the aging and hematopoiesis literature, creating significant prior art concerns; (2) the computational analysis relies heavily on publicly available scRNA-seq datasets; (3) proposed small molecules (Fasudil, rapamycin, cromolyn sodium) are existing drugs with known mechanisms; (4) no IP has been filed or secured yet, leaving the project vulnerable to being scooped; (5) the competitive landscape in HSC rejuvenation and aging biology is active. The novelty likely lies in the specific combination and temporal coordination rather than individual targets, which is a narrower IP claim.